Delayed Diagnosis in Gynaecological Cancer: Mr Moiad Alazzam Shares His Medico-Legal Expertise
Ardent Expert Chambers Member Mr Moiad Alazzam, Consultant Gynaecological Oncologist, joined INNEG for a specialist webinar examining delayed diagnosis in gynaecological cancer and the clinical questions that can arise when the timing of diagnosis, treatment and outcome is disputed.
The webinar attracted 547 registrations, with 365 attending live, making it one of INNEG’s most well-attended sessions and reflecting the significant interest surrounding oncology-related clinical negligence.
Drawing on his specialist experience in gynaecological oncology, Mr Alazzam explored how diagnostic delays can occur across primary and secondary care, the clinical signs that may warrant further investigation and the importance of establishing what an earlier diagnosis would realistically have changed.
Recognising Red Flags in Gynaecological Cancer
One of the central themes of Mr Alazzam’s session was the importance of recognising symptoms and clinical findings that may require further investigation.
Gynaecological cancers can present in different ways, and symptoms may initially overlap with benign or more common conditions.
This makes the clinical context particularly important.
When reviewing a case retrospectively, an expert may need to consider the nature and progression of symptoms, investigations undertaken, referrals made and the information available to clinicians at each stage of the patient’s pathway.
Mr Alazzam highlighted the importance of assessing those decisions according to what was reasonably apparent at the time, rather than simply working backwards from the eventual cancer diagnosis.
Examining the Diagnostic Pathway
Diagnostic delay may arise at several points across a patient's care.
There may be questions surrounding the initial recognition of symptoms, the timing of referral, interpretation of investigations or the point at which specialist gynaecological oncology input was sought.
For an expert witness, establishing that cancer could theoretically have been diagnosed earlier is only part of the analysis.
The more detailed question is whether the clinical presentation at a particular point should reasonably have prompted a different investigation, referral or management decision.
Mr Alazzam’s discussion demonstrated the importance of reconstructing this pathway carefully and considering each clinical decision within its proper context.
Earlier Diagnosis and Cancer Staging
Where a diagnostic delay is identified, one of the most significant questions is whether the cancer would probably have been at a different stage had it been diagnosed earlier.
Cancer staging can have substantial implications for treatment and prognosis, but the relationship between delay and progression is not always straightforward.
An expert may therefore need to consider the likely biological progression of the tumour, the length of the alleged delay and the clinical evidence available at different points in time.
Mr Alazzam explored the importance of distinguishing between an identifiable delay and a delay that can reasonably be said to have changed the patient's disease stage or subsequent clinical course.
The Impact on Treatment Options
Earlier diagnosis may also affect the treatment options available to a patient.
Depending on the cancer type, stage and individual circumstances, treatment may involve surgery, systemic therapy, radiotherapy or a combination of approaches.
An expert reviewing a delayed diagnosis case may therefore need to consider not only when the cancer could have been detected, but what treatment would probably have been recommended at that earlier stage.
That distinction can be crucial when assessing the consequences of a delay.
The relevant outcome may relate to the extent of surgery required, the availability of alternative treatment strategies or the overall treatment burden experienced by the patient.
Fertility and Longer-Term Consequences
For some patients with gynaecological cancer, the consequences of delayed diagnosis may extend beyond cancer treatment and prognosis.
Fertility preservation can become a particularly significant consideration, especially where an earlier-stage cancer may have allowed different surgical or treatment options.
Mr Alazzam examined how the timing and stage of diagnosis can influence whether fertility-sparing treatment is clinically appropriate.
Assessing this retrospectively requires specialist understanding of the cancer involved, the patient's circumstances and the treatment options that would realistically have been available at the relevant time.
This illustrates why the consequences of delayed diagnosis cannot always be captured by survival or disease progression alone.
Separating Delay From Its Consequences
A recurring theme throughout Mr Alazzam’s webinar was the need to separate two distinct questions: whether diagnosis should have occurred earlier and what difference an earlier diagnosis would probably have made.
An avoidable diagnostic delay does not automatically establish that the patient's treatment, prognosis or wider outcome would have been different.
Equally, relatively short delays can sometimes be clinically significant depending on the disease involved and the point at which the patient presented.
Providing an independent opinion therefore requires careful consideration of tumour biology, staging, treatment options and the patient's individual clinical course.
It is this combination of specialist oncology knowledge and detailed retrospective analysis that sits at the centre of Mr Alazzam’s medico-legal work.
Specialist Expertise in Gynaecological Oncology
As a Consultant Gynaecological Oncologist, Mr Alazzam brings specialist knowledge of complex pelvic malignancy, cancer diagnosis, surgical treatment and clinical decision-making to his expert witness practice.
His webinar with INNEG provided an opportunity to demonstrate how that expertise is applied when examining difficult questions surrounding delayed diagnosis, disease progression and treatment.
Rather than viewing delay in isolation, his approach considers the complete clinical pathway: from the earliest presentation and investigations through to diagnosis, staging, treatment options and longer-term consequences.
Mr Moiad Alazzam is a member of Ardent Expert Chambers. View his full member profile to learn more about his specialist expertise and medico-legal practice.
View experts in Gynaecology
View Experts
